SAC StudioThe high-strength, heavy-metal-tested bulk refill for committed users.
Double Wood Boswellia answers a specific question: I've confirmed boswellia helps my joints — what's the best long-haul bulk supply? It's a full-strength standardised extract (1,000 mg per two-capsule serving at 65% boswellic acids, roughly 650 mg of acids per serving — 500 mg extract per cap) in a 240-capsule mega-bottle, at a reasonable cost-per-serving. The standout is testing: Double Wood explicitly third-party tests for heavy metals and microbial contaminants and makes its COAs available on request — a meaningful safeguard for a resin extract.
The trade-offs are the familiar ones: it standardises to total boswellic acids rather than a stated AKBA %, it carries no co-factors, and the big bottle is poor value if boswellia turns out not to help you. This rounds out the list as the committed-user refill, not the first bottle. Here's the full breakdown.
A high standardisation figure — 65% boswellic acids, roughly 650 mg of acids per 1,000 mg two-capsule serving (about 325 mg per capsule) — well above the unstandardised resin that fills the budget aisle. It sits in the strong mid tier, trailing the 5-Loxin / AprèsFlex picks only because it standardises to total boswellic acids rather than a stated AKBA %, the same precision gap as NOW and Nutricost.
The label's suggested serving — two 500 mg capsules — delivers exactly the ~1,000 mg/day of standardised extract Kimmatkar 2003 used, so the trial dose is hit precisely at the suggested-use serving rather than via an oversized single cap. The score sits just below the very top because the trial split its dose three times daily rather than the label's two, a minor kinetic difference rather than a real dosing shortfall.
A real strength, though narrower than first stated: the Certificate of Analysis confirms passed results for heavy metals (lead, mercury, arsenic, cadmium) and microbial contaminants, made in a GMP-certified US facility from globally sourced materials. For a resin extract — where heavy-metal contamination is a real risk — that's a relevant, above-average safeguard for the price tier. The COA doesn't show a separate potency-assay result, and COAs are available on request rather than proactively published, which is why the score sits a touch below the top of this tier.
Roughly $20 for 240 caps (120 servings) works out to about $0.17 per 1,000 mg standardised serving — real but unremarkable value once the true two-capsule serving size is accounted for, not the $0.08-per-1,000-mg figure the per-capsule math had implied. It's still an affordable four-month supply for daily use, though the large bottle is poor value if boswellia turns out not to help you, so it's a refill rather than a first buy.
A clean single-active standardised extract — no proprietary blend, no junk fillers hiding the dose. It scores solidly but not top, because it adds nothing beyond the extract (no turmeric co-factor like NOW, no hypoallergenic standard like Pure Encapsulations) — the deliberate trade for a full-dose, low-cost-per-cap bulk bottle.
“Standardised to 65% boswellic acids, 1,000 mg per 2-capsule serving.”
A genuine, high standardisation figure consistent with the Supplement Facts panel — roughly 650 mg of boswellic acids per 1,000 mg two-capsule serving (500 mg extract / about 325 mg acids per capsule). This is a real, full-strength active spec, not the unstandardised resin that fills the rest of the budget aisle.
“Third-party tested for heavy metals and microbial contaminants.”
The Certificate of Analysis shows passed results for lead, mercury, arsenic, cadmium, and microbial tests (plate count, yeast/mold, coliform, E. coli, staph), run by Canyonside Labs — for a resin extract, that heavy-metal verification is a relevant and meaningful safeguard. The COA doesn't show a separate potency-assay result, and it's available on request rather than proactively published, so we've narrowed the claim to what the COA actually confirms.
“Joint health support.”
This is the label's actual structure/function claim (front label: "Joint Health Support"). Boswellia's joint benefits are backed by real RCTs — Kimmatkar 2003 (PMID 12622457) found a standardised extract reduced knee-OA pain and improved function versus placebo over 8 weeks. The label's suggested dose range (1,000 mg/day, up to 2,000 mg/day at the 4-capsule maximum) sits within that evidence base.
“Full Potency Per Serving.”
Matches the product gallery's own listing language. The two-capsule serving delivers the full disclosed 1,000 mg of 65%-standardised extract (about 650 mg boswellic acids) — a complete, undiluted standardised dose. Double Wood is a value brand, not a clinician-grade marque, and it standardises to total boswellic acids rather than a named AKBA fraction, so "premium" isn't a label claim we can verify.
An earlier version of this review said each capsule delivers 1,000 mg of extract (650 mg boswellic acids), and treated a single cap as a strong stand-alone dose. The Supplement Facts panel reads Serving Size: 2 Capsules — Boswellia Extract (65% Boswellic Acid) 1,000 mg per serving — so each capsule is actually 500 mg of extract (about 325 mg boswellic acids), and the label's suggested use is two capsules per day, not to exceed four. Servings Per Container is 120, making the 240-capsule bottle a four-month supply at the label dose, not four-to-eight months. We re-read the label on Sep 3, 2026 and corrected the dose, supply-length, cost-per-serving, and testing language throughout this review. Dose alignment moved 7.0 → 8.0 (the two-capsule label dose matches the Kimmatkar 2003 window exactly), Cost per standardised serving moved 8.0 → 7.0 (real cost is about $0.17 per 1,000 mg serving, not the $0.08 the per-capsule math implied), and Third-party testing moved 8.0 → 7.5 (the Certificate of Analysis confirms heavy-metal and microbial results but not a separate potency assay, and COAs are available on request rather than proactively published). The overall score recomputes to 7.5, unchanged.
Double Wood's case rests on three things working together: a full 1,000 mg daily dose (two 500 mg capsules at 65% boswellic acids), explicit third-party heavy-metal and microbial testing, and a 240-cap bulk bottle at a reasonable cost-per-dose. The heavy-metal testing is the standout — boswellia is a resin extract, and resins can carry contamination, so independent verification is a real safeguard rather than marketing. For a committed user taking boswellia daily for months, a tested, full-dose bulk supply is exactly the right package.
The label's suggested use is two 500 mg capsules a day, which together deliver the full ~1,000 mg standardised dose Kimmatkar 2003 used. At that dose, the 240-cap bottle lasts four months — a long runway among boswellia bottles. That bulk format is the whole appeal, but it's also why this isn't a first purchase: a four-month supply is too much to commit before you know you respond. Test with a smaller bottle first, then buy this as the refill.
Like NOW (#1), Nutricost (#6), and the other whole-extract picks, Double Wood standardises to total boswellic acids (65%) rather than a stated AKBA percentage — so it trails the pure-play AKBA picks (Life Extension 5-LOXIN #2) on the most potent fraction. The standardisation is high and real, and the heavy-metal testing is a genuine plus; the precision gap is the familiar trade-off of a whole-extract product. If matching the AKBA-enriched evidence exactly is your priority, 5-LOXIN is the pick.
Double Wood has built its reputation on third-party testing and makes its batch COAs available on request, and on this product that means explicit heavy-metal and microbial verification, made in the USA. It isn't a clinician-grade marque, but its testing transparency is above average for the value tier — and crucially, the kind of testing it does (heavy metals on a resin extract) is exactly the kind that matters for this botanical. That's a more relevant quality signal here than it would be for a simple single-molecule supplement.
Position Double Wood correctly and it's a strong buy: it rounds out the list as the full-dose, heavy-metal-tested, low-cost-per-cap bulk supply for someone who already knows boswellia works for them. It's not the bottle to discover boswellia with (too much commitment), the AKBA-precision pick (that's 5-LOXIN #2), or the co-factor pick (NOW #1) — and it shouldn't be bought expecting those. Buy it as the long-haul refill once a smaller pack has proven the supplement helps your joints.
Double Wood Boswellia is the sensible bulk-buy once you've confirmed boswellia helps your joints — a full-strength extract (1,000 mg per two-capsule serving at 65% boswellic acids) in a 240-cap mega-bottle at a reasonable cost-per-serving, and notably third-party tested for heavy metals, which matters for a resin extract. You give up AKBA precision (it standardises to total boswellic acids, like NOW) and co-factors, but you keep a tested, full-dose, long-runway supply at a fair cost-per-dose. It rounds out the list rather than leading it, and the sequencing matters: don't make it your first bottle. Test boswellia with a smaller, cheaper pack first — Swanson (#5) or Nutricost (#6) — and once you know you respond, switch to Double Wood as the long-haul refill. Choose differently from the start if your priority is AKBA precision (Life Extension 5-LOXIN #2), a complementary co-factor (NOW #1), or a clinician-grade clean label (Pure Encapsulations #4). For a committed user who wants a full-dose, heavy-metal-tested bulk supply, Double Wood is the right answer — two capsules a day, with or without food (label maximum four).
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
A 65%-standardised extract delivering 1,200 mg per two-cap serving at the lowest cost-per-gram on the list, in a 180-cap bottle. The smaller-bottle value pick to test boswellia before committing to the 240-cap Double Wood.
See it on the list →The named AKBA-enriched 5-Loxin extract (~30% AKBA) the strongest trial used. The upgrade if you want maximal AKBA precision rather than a high-strength bulk supply.
See it on the list →The cheapest standardised boswellia on the list in a smaller 100-cap bottle — the low-risk way to test whether boswellia works for you before buying the 240-cap Double Wood refill.
See it on the list →Randomised, double-blind, placebo-controlled crossover trial in knee-osteoarthritis patients: a standardised Boswellia serrata extract significantly reduced knee pain, improved function, and increased walking distance versus placebo over 8 weeks. The efficacy and dosing basis (~333 mg three times daily, ~1,000 mg/day) for a standardised extract like Double Wood's.
Placebo-controlled trial of 5-Loxin (an AKBA-enriched Boswellia extract, ~30% AKBA) at 100 and 250 mg/day in knee osteoarthritis: significant, dose-related pain and function improvements, with benefits within ~7 days at 250 mg. Defines the AKBA-enriched precision tier Double Wood's total-boswellic-acid standardisation sits below.
